Till Milde

List of Publications by Year
in descending order

144	19,210	44069 48	30922 102
papers	citations	h-index	g-index

163	163	163	21849
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 2012, 482, 226-231.	27.8	2,129
2	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
3	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 2012, 22, 425-437.	16.8	1,551
4	HDAC family: What are the cancer relevant targets?. Cancer Letters, 2009, 277, 8-21.	7.2	893
5	The whole-genome landscape of medulloblastoma subtypes. Nature, 2017, 547, 311-317.	27.8	787
6	Dissecting the genomic complexity underlying medulloblastoma. Nature, 2012, 488, 100-105.	27.8	765
7	CD133 expression is not restricted to stem cells, and both CD133+ and CD133â€“ metastatic colon cancer cells initiate tumors. Journal of Clinical Investigation, 2008, 118, 2111-20.	8.2	736
8	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
9	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genetics, 2013, 45, 927-932.	21.4	674
10	Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. Cancer Cell, 2013, 24, 660-672.	16.8	633
11	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. Cancer Cell, 2014, 25, 393-405.	16.8	627
12	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature, 2014, 506, 445-450.	27.8	521
13	Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma. Cancer Cell, 2011, 20, 143-157.	16.8	494
14	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 2016, 131, 821-831.	7.7	478
15	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell, 2016, 29, 379-393.	16.8	438
16	Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature, 2014, 510, 537-541.	27.8	378
17	Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathologica, 2018, 136, 181-210.	7.7	308
18	Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsiveâ€“like behaviors in mice. Nature Medicine, 2010, 16, 598-602.	30.7	281

#	Article	IF	Citations
19	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathologica, 2015, 129, 669-678.	7.7	277
20	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798.	10.7	268
21	Next-generation personalised medicine for high-risk paediatric cancer patients â€“ The INFORM pilot study. European Journal of Cancer, 2016, 65, 91-101.	2.8	262
22	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
23	Molecular Staging of Intracranial Ependymoma in Children and Adults. Journal of Clinical Oncology, 2010, 28, 3182-3190.	1.6	210
24	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathologica, 2016, 131, 903-910.	7.7	203
25	HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth. Clinical Cancer Research, 2010, 16, 3240-3252.	7.0	175
26	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature, 2018, 553, 101-105.	27.8	170
27	Histone deacetylase 10 promotes autophagy-mediated cell survival. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2592-601.	7.1	168
28	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. Acta Neuropathologica, 2018, 136, 239-253.	7.7	118
29	HD-MB03 is a novel GroupÂ3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. Journal of Neuro-Oncology, 2012, 110, 335-348.	2.9	110
30	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discovery, 2021, 11, 2764-2779.	9.4	110
31	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathologica, 2018, 136, 327-337.	7.7	104
32	TP53 Mutation Is Frequently Associated With CTNNB1 Mutation or MYCN Amplification and Is Compatible With Long-Term Survival in Medulloblastoma. Journal of Clinical Oncology, 2010, 28, 5188-5196.	1.6	100
33	Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. Nature Reviews Cancer, 2019, 19, 420-438.	28.4	98
34	Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. Journal of Clinical Investigation, 2006, 116, 3277-3291.	8.2	95
35	The molecular landscape of ETMR at diagnosis and relapse. Nature, 2019, 576, 274-280.	27.8	94
36	Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. Cancer Cell, 2020, 38, 44-59.e9.	16.8	94

#	Article	IF	Citations
37	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. Nature, 2020, 580, 396-401.	27.8	94
38	Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2â€‰years of age â€“ a multicenter retrospective study. Orphanet Journal of Rare Diseases, 2019, 14, 96.	2.7	90
39	MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Research, 2013, 41, 6018-6033.	14.5	87
40	A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Acta Neuropathologica, 2011, 122, 637-650.	7.7	77
41	Response to trametinib treatment in progressive pediatric low-grade glioma patients. Journal of Neuro-Oncology, 2020, 149, 499-510.	2.9	68
42	An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. Journal of Clinical Investigation, 2011, 121, 1344-1348.	8.2	68
43	Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. Acta Neuropathologica Communications, 2015, 3, 22.	5.2	66
44	Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opinion on Investigational Drugs, 2009, 18, 1605-1617.	4.1	64
45	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precision Oncology, 2020, 4, 561-571.	3.0	62
46	MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. Acta Neuropathologica, 2012, 123, 529-538.	7.7	60
47	Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors. Cell Cycle, 2018, 17, 811-822.	2.6	60
48	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. Clinical Cancer Research, 2019, 25, 1851-1866.	7.0	55
49	GRHL1 Acts as Tumor Suppressor in Neuroblastoma and Is Negatively Regulated by MYCN and HDAC3. Cancer Research, 2014, 74, 2604-2616.	0.9	54
50	Predisposition to cancer in children and adolescents. The Lancet Child and Adolescent Health, 2021, 5, 142-154.	5.6	53
51	Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. European Journal of Cancer, 2019, 114, 27-35.	2.8	51
52	Angiomodulin Is a Specific Marker of Vasculature and Regulates Vascular Endothelial Growth Factor-Aâ€“Dependent Neoangiogenesis. Circulation Research, 2009, 105, 201-208.	4.5	47
53	Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis. Leukemia, 2017, 31, 2048-2056.	7.2	47
54	Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance. Cell Death and Disease, 2017, 8, e3013-e3013.	6.3	43

#	Article	IF	Citations
55	Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. Oncotarget, 2017, 8, 11460-11479.	1.8	43
56	Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. Acta Neuropathologica, 2019, 138, 827-835.	7.7	42
57	Nestin Expression Identifies Ependymoma Patients with Poor Outcome. Brain Pathology, 2012, 22, 848-860.	4.1	40
58	Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. Neuro-Oncology, 2017, 19, 1607-1617.	1.2	39
59	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusionâ€“Positive Supratentorial Ependymomas. Cancer Discovery, 2021, 11, 2230-2247.	9.4	39
60	Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma. Cancer Research, 2020, 80, 5393-5407.	0.9	38
61	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nature Communications, 2019, 10, 2400.	12.8	37
62	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. Acta Neuropathologica, 2021, 142, 841-857.	7.7	36
63	Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. Clinical Epigenetics, 2019, 11, 188.	4.1	27
64	Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. Oncotarget, 2016, 7, 61860-61873.	1.8	27
65	Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. Science Translational Medicine, 2021, 13, .	12.4	26
66	HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells. Anti-Cancer Drugs, 2008, 19, 849-857.	1.4	24
67	Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma. Genes Chromosomes and Cancer, 2009, 48, 229-238.	2.8	24
68	Retinal angiogenesis suppression through small molecule activation of p53. Journal of Clinical Investigation, 2013, 123, 4170-4181.	8.2	24
69	INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. BMC Cancer, 2020, 20, 523.	2.6	24
70	Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. Nature Communications, 2021, 12, 5530.	12.8	24
71	Molecular approaches to ependymoma. Current Opinion in Neurology, 2012, 25, 745-750.	3.6	22
72	Targeting of histone deacetylases in brain tumors. CNS Oncology, 2013, 2, 359-376.	3.0	22

#	Article	IF	Citations
73	Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma. Neuro-Oncology, 2021, 23, 226-239.	1.2	22
74	Emerging Insights into the Ependymoma Epigenome. Brain Pathology, 2013, 23, 206-209.	4.1	21
75	Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib. Pediatric Blood and Cancer, 2018, 65, e26893.	1.5	21
76	Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts. Pharmaceuticals, 2020, 13, 345.	3.8	19
77	Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas. Neuro-Oncology, 2021, 23, 1634-1646.	1.2	19
78	Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma. Journal of Personalized Medicine, 2020, 10, 290.	2.5	18
79	Characterization of a novel <scp>OTX</scp>2â€driven stem cell program in Group 3 and Group 4 medulloblastoma. Molecular Oncology, 2018, 12, 495-513.	4.6	16
80	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. Acta Neuropathologica, 2021, 142, 1065-1069.	7.7	16
81	SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk Medulloblastoma. Cancers, 2021, 13, 6077.	3.7	16
82	Abstract 3687: An integrative genomics approach identifies distinct molecular and epigenetic subgroups of pediatric glioblastoma. Cancer Research, 2012, 72, 3687-3687.	0.9	15
83	Quantification of vorinostat and its main metabolites in plasma and intracellular vorinostat in PBMCs by liquid chromatography coupled to tandem mass spectrometry and its relation to histone deacetylase activity in human blood. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 964, 212-221.	2.3	14
84	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. Brain Pathology, 2016, 26, 506-516.	4.1	14
85	A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells. Molecular Cancer Therapeutics, 2020, 19, 1736-1750.	4.1	13
86	Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models. Cancers, 2022, 14, 849.	3.7	13
87	Accurate calling of KIAA1549â€BRAF fusions from DNA of human brain tumours using methylation arrayâ€based copy number and gene panel sequencing data. Neuropathology and Applied Neurobiology, 2021, 47, 406-414.	3.2	12
88	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. Acta Neuropathologica Communications, 2022, 10, 5.	5.2	12
89	Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study. Cancers, 2022, 14, 471.	3.7	9
90	Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making â€" A Selected Case Series. Klinische Padiatrie, 2018, 230, 305-313.	0.6	8

#	Article	IF	Citations
91	Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. Cancers, 2021, 13, 4476.	3.7	8
92	Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. Journal of Neuro-Oncology, 2021, 155, 193-202.	2.9	6
93	Multifocal Osteochondroma After Repeated Irradiation in a Boy With Hodgkin Disease. Journal of Pediatric Hematology/Oncology, 2005, 27, 344-345.	0.6	5
94	INFORM2 exploratory multinational phase I/II combination study of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies: INFORM2 NivEnt.. Journal of Clinical Oncology, 2019, 37, TPS10065-TPS10065.	1.6	5
95	The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma. Cancers, 2022, 14, 679.	3.7	4
96	Reply to J.C. Lindsey et al. Journal of Clinical Oncology, 2011, 29, e348-e349.	1.6	2
97	MEDU-01. HDACi AND PLK1i ACT SYNERGISTICALLY IN MYC-AMPLIFIED MEDULLOBLASTOMA. Neuro-Oncology, 2019, 21, ii103-ii103.	1.2	1
98	GENE-12. ANAPLASTIC NEUROEPITHELIAL TUMOR WITH CONDENSED NUCLEI (ANTCON): A NOVEL BRAIN TUMOR ENTITY WITH RECURRENT NTRK FUSION. Neuro-Oncology, 2019, 21, ii83-ii83.	1.2	1
99	Retinoblastoma with late metastatic spreadâ€"a case report. Pediatric Blood and Cancer, 2019, 66, e27656.	1.5	1
100	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i107-i107.	1.2	1
101	LGG-14. LOGGIC (Low Grade Glioma in Children) Core BioClinical Data Bank: Establishment and added clinical value of an international molecular diagnostic registry for pediatric low-grade glioma patients. Neuro-Oncology, 2022, 24, i90-i90.	1.2	1
102	Ependymoma. Molecular Pathology Library, 2015, , 67-75.	0.1	0
103	LG-27DKFZ-BT66 - A NOVEL PILOCYTIC ASTROCYTOMA MODEL FOR PRECLINICAL DRUG TESTING. Neuro-Oncology, 2016, 18, iii84.3-iii84.	1.2	0
104	MB-57INTERACTION OF HDAC2 AND MYC IN GROUP 3 MEDULLOBLASTOMA - A NOVEL THERAPEUTIC TARGET. Neuro-Oncology, 2016, 18, iii110.1-iii110.	1.2	0
105	PCM-16MOLECULAR CHARACTERIZATION OF ORTHOTOPIC PATIENT-DERIVED XENOGRAFT MODELS OF PEDIATRIC BRAIN TUMORS. Neuro-Oncology, 2016, 18, iii142.3-iii142.	1.2	0
106	LGG-11. REGULATION OF ONCOGENE-INDUCED SENESCENCE IN PILOCYTIC ASTROCYTOMA. Neuro-Oncology, 2018, 20, i106-i106.	1.2	0
107	MBRS-12. INTERFERENCE WITH THE FUNCTION OF MYC IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i130-i130.	1.2	0
108	LGG-11. ESTABLISHMENT OF A HUMAN 3-DIMENSIONAL LOW-GRADE GLIOMA TUMOR MODEL IN INDUCED PLURIPOTENT STEM CELL DERIVED BRAIN ORGANOIDS. Neuro-Oncology, 2019, 21, ii101-ii101.	1.2	0

#	Article	IF	Citations
109	LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. Neuro-Oncology, 2019, 21, ii102-ii102.	1.2	0
110	EMBR-01. CLASS I HDAC INHIBITORS AND PLK1 INHIBITORS SYNERGIZE IN MYC-AMPLIFIED MEDULLOBLASTOMA. Neuro-Oncology, 2021, 23, i5-i5.	1.2	0
111	EMBR-11. SYNERGISTIC DRUG COMBINATIONS FOR THE TREATMENT OF MYC AMPLIFIED GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2021, 23, i7-i8.	1.2	0
112	LGG-04. MULTIOMIC ANALYSIS OF MAPK PATHWAY ACTIVITY IN PEDIATRIC PILOCYTIC ASTROCYTOMA. Neuro-Oncology, 2021, 23, i31-i32.	1.2	0
113	EPCT-06. PRECISION ONCOLOGY IN THE PEDIATRIC TARGETED THERAPY 2.0 PROGRAM. Neuro-Oncology, 2021, 23, i47-i48.	1.2	0
114	LGG-11. BH3-MIMETICS TARGETING BCL-XL SELECTIVELY IMPACT THE SENESCENT COMPARTMENT OF PILOCYTIC ASTROCYTOMA. Neuro-Oncology, 2021, 23, i33-i34.	1.2	0
115	Abstract 31: Subgroup-specific molecular alterations may explain the tremendous clinical heterogeneity of intracranial ependymoma. , 2010, , .		0
116	Abstract 3453: Induction of differentiation in high-risk ependymoma stem-like cells by treatment with the HDAC inhibitor Vorinostat. , 2011, , .		0
117	Abstract 3458: Activated BRAF induces pilocytic astrocytomas in mice. , 2011, , .		0
118	Progressively Metastasizing Ependymoma: Genomic Aberrations. , 2012, , 297-306.		0
119	Abstract 3094: Epigenetic classification of ependymal brain tumors across age groups. , 2014, , .		0
120	Abstract 1935: Molecular characterization of orthotopic patient-derived xenograft models of pediatric brain tumors. , 2017, , .		0
121	Abstract 509: Genomic profiling of acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link betweenATMmutations and chromothripsis. , 2017, , .		0
122	Establishment of a 3-dimensional Low-grade Glioma Model in Induced Pluripotent Stem-cell-derived Brain Organoids. , 2019, 50, .		0
123	LGG-14. MULTI-OMIC ANALYSIS OF MAPK ACTIVATION IN PEDIATRIC PILOCYTIC ASTROCYTOMA. Neuro-Oncology, 2020, 22, iii368-iii368.	1.2	0
124	LGG-17. SYNERGISTIC ACTIVITY OF MAPK INHIBITOR CLASSES REVEALED BY A NOVEL CELL-BASED MAPK ACTIVITY PEDIATRIC LOW-GRADE GLIOMA ASSAY. Neuro-Oncology, 2020, 22, iii369-iii369.	1.2	0
125	EPEN-18. CROSS-SPECIES GENOMICS IDENTIFIES GLI2 AS AN ONCOGENE OF C11orf95 FUSION-POSITIVE SUPRATENTORIAL EPENDYMOMA. Neuro-Oncology, 2020, 22, iii311-iii311.	1.2	0
126	EPEN-21. IMPAIRED NEURONAL-GLIAL FATE SPECIFICATION IN PEDIATRIC EPENDYMOMA REVEALED BY SINGLE-CELL RNA-SEQ. Neuro-Oncology, 2020, 22, iii311-iii312.	1.2	0

#	Article	IF	Citations
127	MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS. Neuro-Oncology, 2020, 22, iii388-iii388.	1.2	0
128	EPEN-18. Oncogenic 3D genome conformations identify novel therapeutic targets in ependymoma. Neuro-Oncology, 2022, 24, i42-i42.	1.2	0
129	MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) andin vivo validation. Neuro-Oncology, 2022, 24, i168-i169.	1.2	0
130	MEDB-38. Significance of CSF cytology and neurologic deterioration in relapsed medulloblastomas in the German HIT-REZ-97/-2005 Studies and the HIT-REZ-Register. Neuro-Oncology, 2022, 24, i113-i114.	1.2	0
131	OTHR-32. The Pediatric Targeted Therapy 2.0 registry: robust molecular diagnostics for precision oncology. Neuro-Oncology, 2022, 24, i154-i154.	1.2	0
132	PATH-13. Methylation analysis in the diagnosis of pediatric CNS tumors; a single center experience. Neuro-Oncology, 2022, 24, i161-i161.	1.2	0
133	LGG-17. Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma. Neuro-Oncology, 2022, 24, i91-i91.	1.2	0
134	LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma. Neuro-Oncology, 2022, 24, i91-i92.	1.2	0
135	LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics. Neuro-Oncology, 2022, 24, i93-i93.	1.2	0
136	MEDB-41. Identifying a subgroup of patients with early childhood sonic hedgehog-activated medulloblastoma with unfavorable prognosis after treatment with radiation-sparing regimens including intraventricular methotrexate. Neuro-Oncology, 2022, 24, i114-i115.	1.2	0
137	MEDB-36. Clinical and molecular heterogeneity withinMYC andMYCN amplified medulloblastoma. Neuro-Oncology, 2022, 24, i113-i113.	1.2	0
138	NFB-13. Rhabdoid Tumor Predisposition Syndrome (RTPS) â€“ Finding Evidence by systematic Analyses. Neuro-Oncology, 2022, 24, i130-i131.	1.2	0
139	LGG-27. Molecular implications of mitogen-activated protein kinase pathway inhibition by the MEK inhibitor trametinib in BRAF-fusion-driven pediatric pilocytic astrocytoma. Neuro-Oncology, 2022, 24, i94-i94.	1.2	0
140	DDEL-01. The role of key pharmacodynamic and pharmacokinetic parameters in drug response prediction of pediatric tumors in the precision oncology study INFORM. Neuro-Oncology, 2022, 24, i33-i34.	1.2	0
141	ATRT-05. Infants and newborns with atypical teratoid/rhabdoid tumors (ATRT) and extracranial malignant rhabdoid tumors: a unique and challenging population. Neuro-Oncology, 2022, 24, i2-i3.	1.2	0
142	LGG-26. Predicting MAPK inhibitor sensitivity in pediatric low-grade gliomas with novel gene expression-derived signatures. Neuro-Oncology, 2022, 24, i93-i94.	1.2	0
143	HGG-61.Landscape of cancer predisposition in pediatric high-grade glioma. Neuro-Oncology, 2022, 24, i76-i76.	1.2	0
144	Multiomics analysis of pediatric solid tumors within the INFORM precision oncology study: From functional drug profiling to biomarker identification.. Journal of Clinical Oncology, 2022, 40, 10036-10036.	1.6	0